JP2012510802A - 完全ヒトインフルエンザｍ２特異的抗体 - Google Patents

完全ヒトインフルエンザｍ２特異的抗体 Download PDF

Info

Publication number
JP2012510802A
JP2012510802A JP2011538980A JP2011538980A JP2012510802A JP 2012510802 A JP2012510802 A JP 2012510802A JP 2011538980 A JP2011538980 A JP 2011538980A JP 2011538980 A JP2011538980 A JP 2011538980A JP 2012510802 A JP2012510802 A JP 2012510802A
Authority
JP
Japan
Prior art keywords
seq
peptide
influenza
monoclonal antibody
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2011538980A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012510802A5 (https=
Inventor
マーティン バッハマン
モニカ バウアー
ロジャー ビアリー
ニコール シュミッツ
Original Assignee
インターセル アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インターセル アーゲー filed Critical インターセル アーゲー
Publication of JP2012510802A publication Critical patent/JP2012510802A/ja
Publication of JP2012510802A5 publication Critical patent/JP2012510802A5/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2011538980A 2008-12-04 2009-11-30 完全ヒトインフルエンザｍ２特異的抗体 Ceased JP2012510802A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP08170749 2008-12-04
EP08170749.9 2008-12-04
EP09173548 2009-10-20
EP09173548.0 2009-10-20
PCT/EP2009/066052 WO2010063675A1 (en) 2008-12-04 2009-11-30 Fully human influenza m2 specific antibodies

Publications (2)

Publication Number Publication Date
JP2012510802A true JP2012510802A (ja) 2012-05-17
JP2012510802A5 JP2012510802A5 (https=) 2013-02-14

Family

ID=42232909

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011538980A Ceased JP2012510802A (ja) 2008-12-04 2009-11-30 完全ヒトインフルエンザｍ２特異的抗体

Country Status (7)

Country Link
US (2) US8460670B2 (https=)
EP (1) EP2365827A1 (https=)
JP (1) JP2012510802A (https=)
CN (1) CN102238963A (https=)
AU (1) AU2009324251A1 (https=)
CA (1) CA2745598A1 (https=)
WO (1) WO2010063675A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4932940B2 (ja) 2007-11-12 2012-05-16 セラクローン サイエンシーズ， インコーポレイテッド インフルエンザの治療および診断のための組成物および方法
AU2009324251A1 (en) 2008-12-04 2010-06-10 Elatos Gmbh Fully human influenza M2 specific antibodies
EP2432803A2 (en) * 2009-05-20 2012-03-28 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
WO2012112489A2 (en) * 2011-02-14 2012-08-23 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005519619A (ja) * 2002-03-13 2005-07-07 麒麟麦酒株式会社 インフルエンザｍ２タンパク質に対するヒトモノクローナル抗体および上記抗体を作製しかつ利用する方法
JP2008522610A (ja) * 2004-12-06 2008-07-03 キリンファーマ株式会社 インフルエンザｍ２タンパク質に対するヒトモノクローナル抗体及びその生産方法及びその使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197502B1 (en) 1997-11-17 2001-03-06 Cytos Biotechnology Ag Expression cloning processes for the discovery characterization, and isolation of genes encoding polypeptides with a predetermined property
US6686168B1 (en) 1999-11-04 2004-02-03 Zymogenetics, Inc. Cell surface display of proteins by recombinant host cells
US20050170334A1 (en) 2002-03-13 2005-08-04 Toshifumi Mikayama Human monoclonal antibodies to influenza M2 protein and methods of making and using same
US8003106B2 (en) 2002-03-13 2011-08-23 Kyowa Hakko Kirin Co., Ltd. Human monoclonal antibodies to influenza M2 protein and methods of making and using same
EP1921142A1 (en) 2006-11-07 2008-05-14 Cytos Biotechnology AG Selection of human monoclonal antibodies by eukaryotic cell display
AU2009324251A1 (en) 2008-12-04 2010-06-10 Elatos Gmbh Fully human influenza M2 specific antibodies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005519619A (ja) * 2002-03-13 2005-07-07 麒麟麦酒株式会社 インフルエンザｍ２タンパク質に対するヒトモノクローナル抗体および上記抗体を作製しかつ利用する方法
JP2008522610A (ja) * 2004-12-06 2008-07-03 キリンファーマ株式会社 インフルエンザｍ２タンパク質に対するヒトモノクローナル抗体及びその生産方法及びその使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6013049500; Ａｎｔｉｖｉｒａｌ　Ｒｅｓｅａｒｃｈ ｖｏｌ．８０, 2008, ｐ．１６８-１７７ *

Also Published As

Publication number Publication date
US20110268740A1 (en) 2011-11-03
WO2010063675A1 (en) 2010-06-10
EP2365827A1 (en) 2011-09-21
US8460670B2 (en) 2013-06-11
US20130109845A1 (en) 2013-05-02
CA2745598A1 (en) 2010-06-10
AU2009324251A1 (en) 2010-06-10
CN102238963A (zh) 2011-11-09

Similar Documents

Publication Publication Date Title
US10654915B2 (en) Antibodies useful in passive influenza immunization
JP2023078352A (ja) 中和抗インフルエンザ結合分子及びその使用
CA2824389A1 (en) Antibodies directed against influenza
EP2630242B1 (en) Identification of antibodies specific for lyssaviruses
EP2065398A1 (en) Human monoclonal nicotine specific antibodies
US12509503B2 (en) Pan-neuraminidase inhibiting antibodies
AU2022361501B9 (en) Anti-sars-cov-2 antibodies and uses thereof i
AU2022361501B2 (en) Anti-sars-cov-2 antibodies and uses thereof i
JP2012510802A (ja) 完全ヒトインフルエンザｍ２特異的抗体
CA2706300C (en) Human monoclonal nicotine specific antibodies
US20240218056A1 (en) Nucleocapsid-specific antibodies and methods for the treatment and prevention of sars-cov-2 infection therewith
US20240043506A1 (en) Sars-cov-2 antibodies
US20220340644A1 (en) Influenza neutralizing antibodies and their uses
HK40061503B (zh) 中和抗流感结合分子及其用途
CN116724049A (zh) 针对sars相关冠状病毒的中和抗体
Battistuzzi Human inhalable antibody fragments neutralizing SARS-CoV-2 variants for COVID-19 therapy
HK1203410B (en) Antibodies useful in passive influenza immunization
HK1250725B (zh) 中和抗流感结合分子及其用途
NZ626716B2 (en) Antibodies useful in passive influenza immunization

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120323

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120323

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120704

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121211

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20130531

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130531

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131003

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131219

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140401

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20141001

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20150219